Will Moderna's hantavirus vaccine mRNA-1080 enter Phase 2 by December 31?
Moderna's mRNA platform enabled a COVID vaccine in record time (63 days from sequence to Phase 1). Their hantavirus candidate mRNA-1080 is in preclinical development. Phase 2 by year-end would be unprecedented speed.
Resolves YES if ClinicalTrials.gov shows Moderna's mRNA-1080 (or equivalent hantavirus mRNA candidate) registered as Phase 2 with first patient enrolled before 2026-12-31.
On settlement the oracle attaches a signed snapshot of each source URL plus a SHA-256 hash of the page content captured at resolution time. Disputes have a 7-day arbitration window.
cited: ClinicalTrials.gov + Moderna press releases
Resolution sources · 3
v2 API returns JSON. Resolves the vaccine-Phase-2 market. Filter `statusModule.overallStatus` and `phase`.
Wire-grade source; resolves the NYT/major-media markets.
Cheap sentiment + earliest-mover for translated regional press. Run a dedup hash on titles + canonical URL.
ETL workers poll these feeds and merge into the resolution oracle.full registry